Kazia Therapeutics analyst ratings
Kazia Therapeutics analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/02/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 10/14/2021 | 837.5% | Maxim Group | → $18 | Initiates Coverage On | → Buy |
| 01/05/2021 | 785.42% | HC Wainwright & Co. | → $17 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析師事務所 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/02/2022 | — | HC Wainwright & Co. | 降級 | 買入 → 中性 | |
| 2021 年 10 月 14 日 | 837.5% | Maxim 集團 | → 18 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 01/05/2021 | 785.42% | HC Wainwright & Co. | → 17 美元 | 啓動覆蓋範圍開啓 | → 購買 |
Kazia Therapeutics Questions & Answers
Kazia Therapeutics 問答
The latest price target for Kazia Therapeutics (NASDAQ: KZIA) was reported by HC Wainwright & Co. on August 2, 2022. The analyst firm set a price target for $0.00 expecting KZIA to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2022年8月2日公佈了Kazia Therapeutics（納斯達克股票代碼：KZIA）的最新目標股價。該分析公司將目標股價設定爲0.00美元，預計KZIA將在12個月內跌至0.00美元（可能下跌-100.00％）。去年有兩家分析公司公佈了評級。
The latest analyst rating for Kazia Therapeutics (NASDAQ: KZIA) was provided by HC Wainwright & Co., and Kazia Therapeutics downgraded their neutral rating.
Kazia Therapeutics（納斯達克股票代碼：KZIA）的最新分析師評級由HC Wainwright & Co. 提供，Kazia Therapeutics下調了中性評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kazia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kazia Therapeutics was filed on August 2, 2022 so you should expect the next rating to be made available sometime around August 2, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Kazia Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Kazia Therapeutics的最後一次評級是在2022年8月2日提交的，因此您應該預計下一個評級將在2023年8月2日左右公佈。
While ratings are subjective and will change, the latest Kazia Therapeutics (KZIA) rating was a downgraded with a price target of $0.00 to $0.00. The current price Kazia Therapeutics (KZIA) is trading at is $1.92, which is out of the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但最新的Kazia Therapeutics（KZIA）評級下調，目標股價爲0.00美元至0.00美元。Kazia Therapeutics（KZIA）目前的交易價格爲1.92美元，超出了分析師的預期區間。